beyond md semaglutide Hani Soudah, MD, PhD, Associate Professor @WashUMedEndo along with collaborators, published a new Weight Loss Clinic Bowie, MD

With retatrutide dosing , the same principle applies

Consistency is key for achieving visible results

Wegovy, a brand of semaglutide, is an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist

The system combines direct and indirect approaches to GLP-1 activation, it is supported by independent 12 week studies, and it provides clear mechanistic rationale such as increasing receptor sites and reducing GLP-1 breakdown by a reported 38 percent

The triple receptor mechanism (GIP, GLP-1, and glucagon) addresses multiple hormonal pathways simultaneously, making it particularly effective for perimenopausal and postmenopausal women